Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ClorNasal
- Development stage
- Unknown
- Lead developer
- Dr. Ferrer Biopharma
- Modality
- Small Molecules
- Administration
- Intranasal
01
Overview
ClorNasal is an over-the-counter intranasal formulation of the first-generation antihistamine chlorpheniramine maleate, developed by Dr. Ferrer BioPharma (marketed in the US by Ferrer Medical Innovations) as a metered nasal spray for the treatment of allergic rhinitis and related upper respiratory symptoms. It acts as a histamine H1 receptor inverse agonist, delivered locally to the nasal mucosa to reduce sneezing, rhinorrhea, itching, and congestion associated with allergy and viral upper respiratory infections, and has also been investigated as an intranasal therapy in COVID-19 due to its antiviral and anti-inflammatory properties.[1][3][7][8][11]
- Brand names
- ClorNasal
02
Targets
HRH1 (Histamine H1 Receptor)RdRp (Coronavirus RNA-dependent RNA polymerase)Mpro (3C-like proteinase of SARS-CoV-2)SARS-CoV-2 spike
Beyond the preview
Go deeper on ClorNasal.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ClorNasal.